beta
Trial Radar AI
Clinical Trial NCT04088422 for Mature B-Cell Lymphoma is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Cell Free DNA in Mature B-cell Lymphoma 320

Recruiting
Clinical Trial NCT04088422 is an observational study for Mature B-Cell Lymphoma that is recruiting. It started on 28 September 2022 with plans to enroll 320 participants. Led by Ruijin Hospital, it is expected to complete by 1 December 2026. The latest data from ClinicalTrials.gov was last updated on 24 February 2023.
Brief Summary
The purpose of this study is to assess whether plasma cell free DNA is an accurate tool that can early and dynamically inform on treatment outcome and an accessible source of tumor DNA to track tumor clonal evolution.
Official Title

Prospective, Observational Study on Cell Free DNA Genotyping as a Tool to Inform Mature B-cell Lymphoma Management

Conditions
Mature B-Cell Lymphoma
Other Study IDs
  • cfDNA
NCT ID Number
NCT04088422
Start Date (Actual)
2022-09-28
Last Update Posted
2023-02-24
Completion Date (Estimated)
2026-12
Enrollment (Estimated)
320
Study Type
Observational
Status
Recruiting
Arms / Interventions
Participant Group/ArmIntervention/Treatment
B-cell lymphoma
peripheral blood collection
peripheral blood collection at treatment start, interm PET/CT, end of treatment PET/CT, one-year and two-year follow-up and or progression or relapse
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
progression free survival
2-year
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
overall survival
2-year
Complete Response rate
6 weeks after treatment
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  • Documented diagnosis of mature B-cell tumor according to WHO 2008 criteria
  • 18 years or older

  • Chemotherapy before
  • Other tumors
Ruijin Hospital logoRuijin Hospital
Study Responsible Party
Zhao Weili, Principal Investigator, Professor, Ruijin Hospital
Study Central Contact
Contact: Weili Zhao, MD，PhD, 64370045, [email protected]
1 Study Locations in 1 Countries

Shanghai Municipality

Ruijin hospital, Shanghai, Shanghai Municipality, 200025, China
Pengpeng XU, MD, PhD, Contact, 86-21-64370045, [email protected]
Weili ZHAO, MD, PhD, Principal Investigator
Pengpeng XU, MD, PhD, Sub-Investigator
Recruiting